Oncology demands platforms that can simultaneously image tumors deep within tissue and deliver targeted therapy at the same location. Current clinical tools cannot meet this need. Existing approaches rely on separate agents for optical imaging and magnetic treatment, forcing clinicians to administer multiple compounds with no guarantee that the diagnostic agent and the therapeutic agent have reached the same site. This fragmented approach complicates treatment and limits the precision of cancer care.
This technology addresses those limitations through a core shell nanoparticle architecture that integrates both functions in a single biocompatible platform. A zinc gallate core provides tunable luminescence in the near infrared range for deep tissue imaging, while a magnetite shell enables localized magnetic hyperthermia to destroy tumor cells. Unlike existing single function nanoparticles, this platform ensures the imaging agent and the therapeutic agent are always co located, delivering real time visibility and targeted treatment simultaneously from one particle.
Transmission electron microscopy images of the ZGO-Fe3O4 core-shell hybrid nanoparticles. The contrast difference between the lighter zinc gallate core and the darker magnetite shell visually confirms the core-shell architecture. The inset panels reveal the yolk shell morphology and a shell thickness of approximately 5.5 nm, with an average total particle diameter of 18.7 nm. This image directly demonstrates the structural precision of the synthesis and the successful encapsulation of the optical core within the magnetic shell.